Literature DB >> 7506298

Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

J A López1, D Andreu, C Carreño, P Whyte, G Taylor, J A Melero.   

Abstract

To study the conformational requirements of epitopes from a conserved antigenic area (area II) of respiratory syncytial (RS) virus fusion (F) glycoprotein, peptides of increasing length containing amino acids essential for these epitopes were synthesized. The synthetic peptides were tested for binding to a panel of neutralizing monoclonal antibodies (MAbs) for this area as well as to rabbit hyperimmune and human convalescent antisera. Antibody binding was dependent on peptide length; thus, a 61-residue peptide spanning amino acids 215 to 275 of the F1 subunit (peptide F215-275) reacted with more antibodies than a shorter (41-residue) peptide F235-275, and this one with more than the (21-residue) peptide F255-275. Most human convalescent sera contained antibodies that reacted with peptides F215-275 and F235-275 but failed to react with F255-275. The results of antibody binding could be related to the structure adopted by the peptides in solution, as determined by circular dichroism spectroscopy and susceptibility of peptides to trypsin digestion. Pretreatment of peptide F215-275 with SDS abolished reactivity with certain MAbs, supporting the notion that higher order structures were needed for antibody binding. High titre anti-peptide antisera were induced in rabbits inoculated with the peptides; however, these sera failed to react with the native F molecule. In mice, only the largest F215-275 peptide induced an anti-peptide response, but their sera reacted poorly with the native F protein and the animals were not protected against an RS virus challenge. These results illustrate the potential use of synthetic peptides in studies of the F protein physical and antigenic structures as well as the problems in designing synthetic RS virus vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506298     DOI: 10.1099/0022-1317-74-12-2567

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Antigenic structure of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; R Bustos; C Orvell; M Berois; J Arbiza; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 3.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

Review 4.  Structural vaccinology starts to deliver.

Authors:  Philip R Dormitzer; Guido Grandi; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2012-12       Impact factor: 60.633

5.  Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

Authors:  Jeanne H Schickli; David C Whitacre; Roderick S Tang; Jasmine Kaur; Heather Lawlor; Cory J Peters; Joyce E Jones; Darrell L Peterson; Michael P McCarthy; Gary Van Nest; David R Milich
Journal:  J Clin Invest       Date:  2015-03-09       Impact factor: 14.808

6.  An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.

Authors:  Xiaozhou Luo; Tao Liu; Ying Wang; Haiqun Jia; Yuhan Zhang; Dawna Caballero; Juanjuan Du; Rongsheng E Wang; Danling Wang; Peter G Schultz; Feng Wang
Journal:  Angew Chem Int Ed Engl       Date:  2015-10-05       Impact factor: 15.336

7.  Identification of a variant subgroup A strain of respiratory syncytial virus.

Authors:  M A Mufson; R J Stanek
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

Review 8.  Structure-Based Vaccine Antigen Design.

Authors:  Barney S Graham; Morgan S A Gilman; Jason S McLellan
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

9.  RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Authors:  Pierre-Louis Hervé; Charlotte Deloizy; Delphyne Descamps; Marie-Anne Rameix-Welti; Jenna Fix; Jason S McLellan; Jean-François Eléouët; Sabine Riffault
Journal:  Nanomedicine       Date:  2016-08-20       Impact factor: 5.307

10.  Structural basis of respiratory syncytial virus neutralization by motavizumab.

Authors:  Jason S McLellan; Man Chen; Albert Kim; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.